Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Mimicking Myeloma Niche Ex Vivo

Jana Jakubikova, PhD, Danka Cholujova, PhD, Richard W Groen, PhD, Jungnam Joo, PhD, Sun-Young Kong, MD PhD, Teru Hideshima, MD PhD, Rikio Suzuki, MDPhD, Jan Sedlak, PhD, Constantine S Mitsiades, MD PhD, David M Dorfman, MD PhD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Paul G. Richardson, MD PhD, Kenneth Anderson, MD PhD

Blood (2014) 124 (21): 2076.

https://doi.org/10.1182/blood.V124.21.2076.2076

Published: 2014

Journal Articles

Nanoparticle Arsenic Compound Realgar Effectively Targets Myeloma Stem-Like Side Population

Jana Jakubikova, PhD, Teru Hideshima, MD, PhD, Richard W.J. Groen, PhD, Danka Cholujova, PhD, Zdenka Bujnakova, PhD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Constantine S. Mitsiades, MD, PhD, Peter Balaz, PhD, Jan Sedlak, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 4455.

https://doi.org/10.1182/blood.V122.21.4455.4455

Published: 2013

Journal Articles

Myeloma Patient-Derived Mesenchymal Stem Cells Grown In 3-D Culture Induce Primary Myeloma Cell Proliferation and Resistance To Therapy

Jana Jakubikova, PhD, Richard W.J. Groen, PhD, Teru Hideshima, MD, PhD, Danka Cholujova, PhD, Jan Sedlak, PhD, Constantine S. Mitsiades, MD, PhD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 1912.

https://doi.org/10.1182/blood.V122.21.1912.1912

Published: 2013

Journal Articles

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

Jana Jakubikova, Sophia Adamia, Maria Kost-Alimova, Steffen Klippel, David Cervi, John F. Daley, Dana Cholujova, Sun-Young Kong, Merav Leiba, Simona Blotta, Melissa Ooi, Jake Delmore, Jacob Laubach, Paul G. Richardson, Jan Sedlak, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2011) 117 (17): 4409–4419.

https://doi.org/10.1182/blood-2010-02-267344

Published: 2011

Includes: Supplemental data

Journal Articles

Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications

Jana Jakubikova, PhD, Melissa Ooi, MD, Steffen Klippel, PhD, Jake Delmore, Jacob P. Laubach, MD, Paul G Richardson, MD, Jan Sedlak, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2010) 116 (21): 5016.

https://doi.org/10.1182/blood.V116.21.5016.5016

Published: 2010

Journal Articles

Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population.

Jana Jakubikova, PhD, Steffen Klippel, PhD, Efstathios Kastritis, MD, John Daley, Melissa Ooi, MD, Jake Delmore, Jacob P. Laubach, MD, Paul G Richardson, MD, Jan Sedlak, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2010) 116 (21): 1581.

https://doi.org/10.1182/blood.V116.21.1581.1581

Published: 2010

Journal Articles

Combination of Enzastaurin and HDAC Inhibitors Synergically Induce Apoptosis in Lymphoma Cells.

Juraj Bodo, PhD, Jan Sedlak, DSc, Jaroslaw P. Maciejewski, MD, PhD, Eric D. Hsi, MD

Blood (2009) 114 (22): 4783.

https://doi.org/10.1182/blood.V114.22.4783.4783

Published: 2009

Journal Articles

Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications.

Jana Jakubikova, David N. Cervi, John F. Daley, Danka Cholujova, Melissa G. Ooi, Steffen Klippel, Simona Blotta, Merav Leiba, Jake Delmore, Douglas McMillin, Efstathios Kastritis, Jacob Laubach, Paul Richardson, Jan Sedlak, Kenneth C. Anderson, Constantine S. Mitsiades, M.D., Ph.D

Blood (2009) 114 (22): 954.

https://doi.org/10.1182/blood.V114.22.954.954

Published: 2009

Journal Articles

Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs

Jana Jakubikova, Jan Sedlak, Steffen Klippel, Merav Leiba, Yu-Tzu Tai, Teru Hideshima, Klaus Podar, Dharminder Chauhan, Noopur Raje, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2008) 112 (11): 2648.

https://doi.org/10.1182/blood.V112.11.2648.2648

Published: 2008

NARROW

Mimicking Myeloma Niche Ex Vivo

Nanoparticle Arsenic Compound Realgar Effectively Targets Myeloma Stem-Like Side Population

Myeloma Patient-Derived Mesenchymal Stem Cells Grown In 3-D Culture Induce Primary Myeloma Cell Proliferation and Resistance To Therapy

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications

Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population.

Combination of Enzastaurin and HDAC Inhibitors Synergically Induce Apoptosis in Lymphoma Cells.

Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications.

Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only